Related Experiment Video
Updated: Oct 12, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Incretins in the Therapy of Diabetic Kidney Disease
Agnieszka Przezak1, Weronika Bielka1, Andrzej Pawlik1
1Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland.
Abstract:
Diabetic kidney disease is a microvascular complication that occurs in patients with diabetes. It is strongly associated with increased risk of kidney replacement therapy and all-cause mortality. Incretins are peptide hormones derived from the gastrointestinal tract, that besides causing enhancement of insulin secretion after oral glucose intake, participate in many other metabolic processes. Antidiabetic drug classes, such as dipeptidyl peptidase 4 inhibitors and glucagon-like peptide receptor agonists, which way of action is based on incretins facility, not only show glucose-lowering properties but also have nephroprotective functions. The aim of this article is to present the latest information about incretin-based therapy and its influence on diabetic kidney disease appearance and progression, point its potential mechanisms of kidney protection and focus on future therapeutic possibilities bound with these two antidiabetic drug classes.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Chronic Kidney Disease III: Interprofessional Care
Oral Hypoglycemic Agents: Glinides
Acute Kidney Injury V: Interprofessional Care
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...

